Number Needed to Treat and Number Needed to Harm From Two Phase 3 Studies of Sublingual Dexmedetomidine for Treating Acute Agitation in Patients With Schizophrenia and Bipolar Disorder

Autor: Citrome L, Risinger R, Rajachandran L, Patton E, Robison H

Publikováno v: CNS Spectrums. 28:226-226

BackgroundEpisodes of acute agitation can occur in individuals who suffer from schizophrenia or bipolar disorder and these can be a significant challenge for patients and for those who provide care to them. Sublingual dexmedetomidine is a selective a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bd5c24d0f74c306f45409d2173e9f29d
https://doi.org/10.1017/s1092852923001475

Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial.

Autor: Jones JD; Division on Substance Use Disorders, Department of Psychiatry, New York State Psychiatric Institute and Columbia University Irving Medical Center, New York, NY, USA., Rajachandran L; BioXcel Therapeutics, Inc, New Haven, CT, USA., Yocca F; BioXcel Therapeutics, Inc, New Haven, CT, USA., Risinger R; BioXcel Therapeutics, Inc, New Haven, CT, USA., De Vivo M; BioXcel Therapeutics, Inc, New Haven, CT, USA., Sabados J; BioXcel Therapeutics, Inc, New Haven, CT, USA., Levin FR; Division on Substance Use Disorders, Department of Psychiatry, New York State Psychiatric Institute and Columbia University Irving Medical Center, New York, NY, USA., Comer SD; Division on Substance Use Disorders, Department of Psychiatry, New York State Psychiatric Institute and Columbia University Irving Medical Center, New York, NY, USA.

Publikováno v: The American journal of drug and alcohol abuse [Am J Drug Alcohol Abuse] 2023 Jan 02; Vol. 49 (1), pp. 109-122. Date of Electronic Publication: 2023 Jan 11.

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial.

Autor: Citrome L; Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York.; Corresponding author: Leslie Citrome, MD, MPH, 11 Medical Park Drive, Ste 102, Pomona, NY 10970 (nntman@gmail.com)., Preskorn SH; Kansas University School of Medicine-Wichita, Wichita, Kansas., Lauriello J; Department of Psychiatry and Human Behavior, Thomas Jefferson University, Philadelphia, Pennsylvania., Krystal JH; Department of Psychiatry, Yale University, New Haven, Connecticut., Kakar R; Segal Trials, Fort Lauderdale, Florida., Finman J; Jupiter Point Pharma Consulting, LLC, Groton, Connecticut., De Vivo M; BioXcel Therapeutics, Inc., New Haven, Connecticut., Yocca FD; BioXcel Therapeutics, Inc., New Haven, Connecticut., Risinger R; BioXcel Therapeutics, Inc., New Haven, Connecticut., Rajachandran L; BioXcel Therapeutics, Inc., New Haven, Connecticut.

Publikováno v: The Journal of clinical psychiatry [J Clin Psychiatry] 2022 Oct 03; Vol. 83 (6). Date of Electronic Publication: 2022 Oct 03.

Sublingual Dexmedetomidine vs Placebo and Acute Agitation Associated With Bipolar Disorder-Reply.

Autor: Preskorn SH; Kansas University School of Medicine-Wichita., Risinger R; BioXcel Therapeutics Inc, New Haven, Connecticut., Kakar R; Segal Trials, Fort Lauderdale, Florida.

Publikováno v: JAMA [JAMA] 2022 Jul 12; Vol. 328 (2), pp. 214-215.

72 Orally Dissolving, Thin Film Dexmedetomidine (BXCL501) Demonstrates Significant Reduction in Agitation Across a Range of Agitation Severity in Patients With Schizophrenia and Bipolar Disorder

Autor: Zeller, S., Benabou, R., Risinger, R., Robison, H.

Publikováno v: In Annals of Emergency Medicine October 2021 78(4) Supplement:S29-S30